For patients with stage III melanoma with BRAF V600E or V600K mutations, 12 months of adjuvant dabrafenib plus trametinib results in increased survival without relapse or distant metastasis at 5 years.
Predictors of dermatoscopic melanoma were investigated in a study that revealed a novel finding.
A study sought to establish prevalence of HF-BCC in the US and the characterization of patients with HF-BCC in the US.
The extent of Hutchinson’s nail sign may be a useful prognostic indicator in patients with subungual melanoma.
The approval was based on data from the multicenter, double-blind, placebo-controlled phase 3 IMspire150 study.
Use of pembrolizumab is supported among patients with advanced melanoma, regardless of BRAF V600E/K mutation status or prior receipt of a BRAFi with or without MEKi therapy.
Questioning the seasonal variations in the diagnosis of skin melanoma yields interesting findings.
New tools examine the rate of mutation accumulation in melanoma, and the effect of sex and age on tumor development.
For patients with melanoma treated with immune checkpoint inhibitors (ICIs), vitamin D intake is associated with a reduced risk for ICI colitis.
Because the TNF-α pathway plays a critical role in tumor surveillance, there is concern that inhibition of this pathway could predispose patients to certain malignancies.
